Kornimate/medical-research-clean huggingface dataset:
synchronous telerehabilitation vs face to face method for upper extremity functions in children with hemiparetic cp

Conditions: Cerebral Palsy

Summary: the aim of this study is to investigate the effectiveness of synchronous telerehabilitation on improving upper extremity function in children with hemiparetic cerebral palsy.

46 children with hemiparetic cerebral palsy who meet the inclusion criteria and agree to participate in the study will be included. the participants will be randomly divided into two groups. the groups are: a) the synchronous telerehabilitation group; b) face to face rehabilitation group. both groups will receive physiotherapy 2 days a week (1 session of 45 minutes) for 12 weels, for a total of 24 sessions. evaluations will be made at baseline and the end of the treatment.

Eligibility criteria:
inclusion criteria: * presence of confirmed hemiparetic cerebral palsy * manual ability classification system ≤ 3 * age between 6 and 18 * absence of major visual and/or auditory deficits * sufficient cooperation to comprehend and complete the test procedure and participate in treatment * family members being active mobile phone or computer and internet users exclusion criteria: * seizures uncontrolled by therapy * surgery and/or botulinum toxin-a injections in the upper limb within 6 months prior to the baseline assessment * having a disabling behavioral disorder to treatment * family's discontinuation of treatment
retrospective data analysis pelvigynious/endogynious

Conditions: Prolapse; Sacrocolpopexy; Pelvic Organ Prolapse (POP)

Summary: the retrospective patient chart review aims to generate additional data to substantiate the safety and performance of endogynious and pelvigynious.


Eligibility criteria:
inclusion criteria: * surgery for pop * implantation of either endogynious or pelvigynious * concomitant procedures are allowed * women minimum 18 years old * written informed consent for surgery exclusion criteria: patients who rule out subsequent contact by the hospital will be excluded. the use of the products is contraindicated in case of: * pregnancy and/or patients who consider future pregnancies * adolescent/ pubescent patients * existence of a known sensitivity/ allergy against plastic materials such as polypropylene, polyester, etc. * any pathology, including known or suspected uterine pathology, which would compromise placement of the implant/mesh (e.g. anatomical distortion or abnormalities) * known anticoagulation disorder * anticoagulant therapy * autoimmune connective tissue disease * renal insufficiency and upper urinary tract obstruction * cancer illnesses of the vagina / cervix / rectum * undergone radiation therapy on the vagina, cervix, rectum * planned or emergency opening of the gastro-intestinal tract, as this could cause a risk of product contamination that could lead to infection that would require removal of the implant/device * active or latent infection especially of the genital system and/or urinary tract

Keywords: sacrocolpopexy sacrocervicopexy surgical mesh laparoscopic mesh
digital equity for stroke approach

Conditions: Stroke; Blood Pressure, High

Summary: a community-academic partnership composed of a state university of new york (suny) downstate health sciences university inter-disciplinary team of scientists (representing public health, medical informatics, vascular neurology/stroke center) and the digital equity community advisory board (deca) will guide our research. this is an nih r21 pilot study. our specific aims are designed to inform the sample design and research priorities for a larger nih r01 experimental study and to serve as a platform for similar studies with other health conditions. we propose a mixed-methods study design with the following aims: 1. assess and build setting, community, and user fit of desa, leveraging qualitative methods and simulation telehealth encounters between the patient and neurologist. 2. conduct a 9-month pilot randomized control trial (rct) of desa in a central brooklyn stroke population to examine the feasibility and preliminary efficacy. we will randomize 50 adults to desa and 30 to usual care. the primary outcome will be bp control. secondary outcomes include the number of bp measurements and medication compliance. our primary hypothesis is that patients randomized to the desa will significantly reduce systolic blood pressure at 9 months. 3. examine barriers and facilitators to the adoption and integration of desa into routine stroke care utilizing key informant interviews and user satisfaction surveys with neurologists and intervention participants.


Eligibility criteria:
inclusion criteria: * african american or afro-caribbean * 18 years or over * experienced a stroke in the last 6 years * a score between 2 and 4 on the modified rankin scale2 * has a formal or informal caregiver (e.g., relative, health aide or other) to assist them in activities of daily living * has a primary care physician at university hospital of brooklyn (uhb) exclusion criteria: * mental illness (severe depression) * dementia * non-english speakers * aphasia * severe dysarthria (slurred speech/impediment)

Keywords: telehealth digital health remote device monitoring health disparities afro-caribbean
iron status and hypoxic pulmonary vascular responses

Conditions: Lung Hypoxia; Pulmonary Arterial Hypertension; Iron Deficiency

Summary: on exposure to hypoxia (low oxygen) the normal response is for pulmonary arterial systolic blood pressure (pasp, blood pressure through the lungs) to increase. we have previously shown that raising iron by giving an infusion of iron into a vein reduces this pressure rise and that lowering iron by giving a drug that binds iron, magnifies this response. this is potentially a clinically important observation since iron-deficient people may be at increased risk of pulmonary hypertension if exposed transiently or permanently to hypoxia due to lung disease or residence at high altitude; furthermore if this were true then intravenous iron could be an important treatment in this patient group in the event of hypoxic exposure. the observed effects of iron on pasp are likely to be because iron levels affect oxygen sensing. low iron levels make the body behave as if exposed to low oxygen by inhibiting the breakdown of the family of oxygen-sensing transcription factors, 'hypoxia inducible factor' or hif. this includes one of the body's normal responses to low oxygen levels - raising blood pressure through the lungs. this study will answer the question (1) do iron-deficient volunteers have a greater rise in pasp with hypoxia than those who are iron-replete, and (2) does giving intravenous iron cause a greater reduction in the rise in pasp in those who are iron-deficient than iron-replete? the purpose of this study is not to test the safety or clinical efficacy of iron which is already known.


Eligibility criteria:
inclusion criteria: * willing and able to give informed consent for participation in the study * men and women aged 18 years or older and generally in good health * detectable tricuspid regurgitation on echocardiography during both normoxia and hypoxia enabling measurement of pulmonary arterial pressure * for iron-deficient volunteers: ferritin ≤15microg/l and transferrin saturation \<16% * for iron-replete volunteers: ferritin ≥20microg/l and transferrin saturation ≥20% exclusion criteria: * haemoglobin \<8.0g/dl * haemoglobinopathy * iron overload defined as ferritin \>300microg/l * hypoxia at rest or on walking (sao2 \<94%) or significant comorbidity that may affect haematinics, pulmonary vascular or ventilatory responses, e.g. current infection, a chronic inflammatory condition, known cardiovalvular lesion or pulmonary hypertension, uncontrolled asthma or chronic obstructive pulmonary disease * exposure to high altitude (\>2,500m) within the previous six weeks or air travel \>4 hours within the previous week * iron supplementation or blood transfusion within the previous 6 weeks * pregnancy or breast feeding

Keywords: hypoxia pulmonary hypertension iron deficiency hypoxic pulmonary vasoconstriction
evaluation of quality-of-life improvements using uroshield device

Conditions: Quality of Life; Catheter-Associated Urinary Tract Infection

Summary: the goal of this pilot study is to test key elements of the full study that will follow, including recruitment and retention strategies, intervention delivery, laboratory testing, data collection methods, and adherence to study protocol. the main questions the investigators aim to answer focus on implementation and practicality: * recruitment feasibility and time to recruit * how well do participants adhere to device protocol? * how often do device components (i.e., actuators and drivers) have to be replaced? * how much time is required for data collection and what sources or methods for data collection are used? results of this pilot study will inform the investigators as to necessary protocol modifications and overall feasibility for the larger randomized clinical trial to follow.

the uroshield® device works by generating ultrasonic waves to interfere with attachment of bacteria inside the catheter, preventing biofilm formation and subsequent infections. this double-blind pilot study aims to recruit 10-20 patients with urinary catheters (urethral or suprapubic catheters) living in nursing homes (nhs) in michigan. patients who consent to participate in the study will be randomized to either the treatment or control group and will have either an active treatment uroshield® device attached or a sham uroshield® device attached to the external tubing of their urinary catheter. participants will wear the device continuously for a maximum of 90 days. assessments of pain and quality-of-life will be conducted by study staff over a maximum of 6 study visits, along with clinical data collection via medical record review. a urine sample and catheter sample will also be collected by study staff at each catheter change (approximately every 30 days).

Eligibility criteria:
inclusion criteria: * male or female age 18+ * indwelling urinary catheter (urethral or suprapubic) in place * written informed consent (and assent, when applicable) obtained from participant or participant's legal representative * able to comply with the requirements of the study exclusion criteria: * pregnant or breastfeeding women * antibiotic use in past 10 days * ineligible catheter type in place (e.g., antimicrobial coated, 3-way catheter, condom catheter, nephrostomy tube, wicking device) * participation in another drug or device study in past 30 days * history of poor compliance to medical treatment regimens * conditions that may severely compromise their ability to complete the study
epidemiologic study evaluating infections in elderly patients

Conditions: Infection

Summary: the purpose of this observational study is to assess the prevalence and demographic and clinical characteristics of infections in elderly people admitted to internal medicine wards in spain, as well as the etiology and resistance pattern for the main causal agents, and outcome.


Eligibility criteria:
inclusion criteria: * patients \> 65 years of age that are hospitalized in an internal medicine ward and have an active infection (skin and soft tissue, intra-abdominal, or respiratory infections) from the community that needs antibiotic treatment * patients must have at least one sample processed for microbiological diagnosis exclusion criteria: * copd exacerbation * urinary tract infections * hospital acquired infections * other infections not in inclusion criteria
preoperative progression of retinal detachment

Conditions: Retinal Detachment

Summary: patients are required to position prior to retinal detachment surgery. we seek to see whether there is a correlation between the performed positioning and retinal detachment progression/regression in fovea-on retinal detachment patients.


Eligibility criteria:
inclusion criteria: * fovea-on retinal detachment * informed consent exclusion criteria: * previous retinal detachment surgery * \>14 days of retinal detachment symptoms * split-fovea retinal detachment * other retinal disease with influence on retinal biomechanics/elasticity (proliferative diabetic retinopathy, wet amd)

Keywords: positioning
acute single meal effects of trout on cardiovascular risk markers and plasma proteome

Conditions: Cardiovascular Diseases; Metabolic Syndrome

Summary: the acute effects of farmed rainbow trout, fed by various feeds versus a control meal with poultry meat on cardiovascular risk markers and plasma protein expression are investigated. the hypotheses of the study are that if the feed are changed from a marine origin to primarily a vegetable origin the content of long chain n-3 poly unsaturated fatty acids (n-3 pufa) will decrease in the meat and thus possibly result in a decreased effect on health. furthermore, the feed of the trouts are also expected to give rise to differences in the human plasma protein profile and fatty acid composition after consumption, which could be associated with physiological effects.

in a controlled, single blinded human single meal study the acute effects of farmed rainbow trout, fed by various feeds versus a control meal with poultry meat on cardiovascular risk markers and plasma protein expression are investigated. 6 healthy men, age 40-70, will be randomized to trout fed on only vegetable, only marine and a mix of different compositions of vegetable and marine feeds. outcome variables are blood pressure, pulse wave analyse, pulse wave velocity, plasma protein profile, and plasma triglycerides. the hypotheses of the study are that if the feed are changed from a marine origin to primarily a vegetable origin the content of long chain n-3 poly unsaturated fatty acids (n-3 pufa) will decrease in the meat and thus possibly result in a decreased effect on health. furthermore, the feed of the trouts are also expected to give rise to differences in the human plasma protein profile and fatty acid composition after consumption, which could be associated with physiological effects.

Eligibility criteria:
inclusion criteria: * non regular smokers * body mass index (18.5-30 kg/m2) * able to eat fish exclusion criteria: * exercise \>10 h/week * chronical diseases (eg. cardiovascular and diabetes) * regular medication * fish oil supplementation * blood donation 2 month prior or during participation * above maximum recommended alcohol intake * blood pressure \>160/100 mm hg

Keywords: cardiovascular heart disease
a phase 2 study of the ketogenic diet vs standard anti-cancer diet guidance for patients with glioblastoma in combination with standard-of-care treatment

Conditions: Glioblastoma Multiforme

Summary: this is a phase 2, randomized two-armed, multi-site study of 170 patients with newly diagnosed glioblastoma multiforme. patients will be randomized 1:1 to receive keto diet, or standard anti-cancer diet. all patients will receive standard of care treatment for their glioblastoma. the keto diet intervention will be for an 18-week period and conducted by trained research dietitians. daily ketone and glucose levels will be recorded to monitor keto diet adherence. this two-armed randomized multi-site study aims to provide evidence to support the hypothesis that a keto diet vs. standard anti-cancer diet improves overall survival in newly diagnosed glioblastoma multiforme patients who receive standard of care treatment.


Eligibility criteria:
inclusion criteria: * adults 18 years or older * newly diagnosed glioblastoma (within 2 months of initial diagnosis by histopathology) * not started standard of care chemotherapy and/or radiation therapy for glioblastoma * karnofsky performance status (kps) ≥ 70 * ability to read, write and understand either english or spanish * written informed consent obtained from subject and ability for subject to comply with the requirements of the study. exclusion criteria: * patients with recurrent glioblastoma * genetic disorders that affect lipid metabolism. including but not limited to pyruvate carboxylase deficiency, porphyria, primary carnitine deficiency, carnitine palmitoyltransferase i or ii deficiency, carnitine translocase deficiency, beta-oxidation defects * inability to wean steroids below 8mg dexamethasone / day or equivalent * body mass index (bmi) \< 21kg/m2, unless the site principal investigator deems safe * currently pregnant or nursing * patients receiving other experimental therapy note: off-label therapy use is permitted * comorbidities that in the opinion of the investigator limit the patient's ability to complete the study * food preferences incompatible with keto diet * using a pacemaker, implantable cardiac defibrillator, neurostimulator, cochlear implants (removable hearing aids permitted), or other electronic medical equipment, unless the site principal investigator deems safe * inability to participant in standard of care mris

Keywords: keto diet
vincristine-induced peripheral neuropathy in adult survivors of childhood and adolescent leukemia

Conditions: Chemotherapy-induced Peripheral Neuropathy

Summary: vincristine is a major anticancer agent in the management of hematological malignancies. one of the main side effects is chemotherapy-induced peripheral neuropathy (cipn). cipn is a characteristic side effect of neurotoxic anticancer drugs. cipn associated with vincristine is typically characterized by distal and symmetrical sensory symptoms (dysesthesia and paresthesia). motor and vegetative symptoms can also be found. the prevalence of cipn associated with vincristine during treatment ranges from 12 to 100% in children (depending on the endpoint). the aim of this cross-sectionnal study will be to explore the cipn prevalence and severity in adult survivors of childhood leukemia and having been treated by vincristine.

adult survivors of chidlhood leukemia and having been treated by vincristine will be contacted from the french childhood cancer survivor study for leukaemia (lea cohort) in order to seek their participation agreement. thereafter patients will received a self-administered questionnaire exploring the chemotherapy-induced peripheral neuropathy and related comorbidities (pain, neuropathic pain, anxiety, depression, health-related quality of life, substance use, physical activity, deprivation). oncological and sociodemographic characteristics of participants will be recorded.

Eligibility criteria:
inclusion criteria: - adult patient (\> 18-year) who received a vincristine-based chemotherapy for hematological malignancy in childhood exclusion criteria: * secondary cancer (leukemia and/or cancer) * active oncological pathology * current cancer treatment * adults protected

Keywords: vincristine-induced peripheral neuropathy pediatric leukemia cancer survivor
early treatment of atrial fibrillation for stroke prevention trial

Conditions: Atrial Fibrillation; Stroke

Summary: east prospectively tests the hypothesis that an early, structured rhythm control therapy based on antiarrhythmic drugs and catheter ablation can prevent atrial fibrillation (af) related complications in patients with af when compared to usual care. patients will be randomized to early therapy or usual care. in the early therapy group, patients will receive either catheter ablation (usually by pulmonary vein isolation), or adequate antiarrhythmic drug therapy at an early time point. the initial therapy will be selected by the local investigator. upon af recurrence, both modalities will be combined. usual care will be conducted following the 2010european society of cardiology ( esc )guidelines for af treatment. early rhythm control therapy will be guided by electrocardiogram (ecg) monitoring.


Eligibility criteria:
inclusion criteria: 1. recent-onset af (≤ 1 year prior to enrolment) 2. at least one ecg within recent 12 months that documents af whereas the af episode must last longer than 30 sec. 3. one of the following: * age \> 75 years or * prior stroke or transient ischemic attack or two of the following: * age \> 65 years, * female sex, * arterial hypertension (chronic treatment for hypertension, estimated need for continuous antihypertensive therapy or resting blood pressure \> 145/90 mmhg), * diabetes mellitus (treated by drugs or insulin) or impaired glucose tolerance * severe coronary artery disease (previous myocardial infarction, cabg or pci) * stable heart failure (nyha ii or lvef \<50%), * left ventricular hypertrophy on echocardiography (more than 15 mm wall thickness), * chronic kidney disease (mdrd stage iii or iv), * peripheral artery disease. 4. provision of signed informed consent. 5. age ≥ 18 years. exclusion criteria: 1. any disease that limits life expectancy to less than 1 year. 2. participation in another clinical trial, either within the past two months or ongoing 3. previous participation in the east trial. 4. pregnant women or women of childbearing potential not on adequate birth control: only women with a highly effective method of contraception \[oral contraception or intra-uterine device (iud)\] or sterile women can be randomized. 5. breastfeeding women. 6. drug abuse. 7. prior af ablation or surgical therapy of af. 8. previous therapy failure on amiodarone, e.g. patients who suffered from symptomatic recurrent af that required escalation of therapy while on amiodarone. 9. patients not suitable for rhythm control of af. 10. severe mitral valve stenosis. 11. prosthetic mitral valve. 12. clinically relevant hepatic dysfunction requiring specific therapy. 13. clinically manifest thyroid dysfunction requiring therapy. after successful treatment of thyroid dysfunction, patients may be enrolled when their thyroid function is controlled. 14. severe renal dysfunction (stage v, requiring or almost requiring dialysis).

Keywords: early treatment rhythm control atrial fibrillation cardiovascular complications
neurobiological, neuropsychological,linguistic and gestural processes and phenomena in individuals with alexithymia

Conditions: Alexithymia

Summary: the syndrome of extremely restricted emotional competence, alexithymia, was originally conceptualized in psychoanalytic research and is now empirically and experimentally studied in clinical psychology and psychological medicine within the context of emotion regulation using neuroscientific techniques. alexithymia refers to an individual's inability or impaired ability to name or express feelings and to distinguish them from the physical consequences of an acute or chronic stress reaction. modern "brain-body-interface" research suggests that alexithymia represents a complex deficiency in cognitive processing and emotional regulatory processes. the neurobiological basis is assumed to be a preconscious, automatic and involuntary information transfer to the amygdalae of acquired representations of emotional contents stored in ventromedial prefrontal cortical areas. alexithymia is not just "emotional coldness", i.e. a limited emotionality, but essentially the detachment of feelings from language. in alexithymia the link between affective phenomena and language, understood as media-supported sign practices, is insufficient or even absent. the purpose of our observational study is to better understand the neurobiological and neuropsychological as well as linguistic and gestural processes and determinants of this phenomenon


Eligibility criteria:
inclusion criteria: * scoring high on the tas-20 exclusion criteria: * personal history of a mental disorder * currently mentally ill

Keywords: alexithymia